| Human immunodeficiency virus I infection
Complera vs Isentress
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Complera vs Isentress with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIsentress has a higher rate of injection site reactions vs Complera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Isentress but not Complera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Complera
Isentress
At A Glance
Oral
Once daily
NRTI/NNRTI fixed-dose combination
Oral
Once or twice daily
HIV-1 integrase strand transfer inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet orally once daily with food for adults and pediatric patients weighing at least 35 kg; not recommended in patients with estimated creatinine clearance below 50 mL/min.
Pregnancy One tablet once daily may be continued in virologically suppressed patients (HIV-1 RNA less than 50 copies/mL); monitor viral load closely due to lower rilpivirine exposures during pregnancy.
Rifabutin coadministration Add one additional 25 mg rilpivirine (Edurant) tablet once daily with a meal for the duration of rifabutin coadministration.
Human immunodeficiency virus I infection (adults, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily or 400 mg twice daily orally, with or without food.
Human immunodeficiency virus I infection (adults, treatment-experienced) 400 mg twice daily orally, with or without food.
Human immunodeficiency virus I infection (adults, coadministration with rifampin) 800 mg (2 x 400 mg) twice daily orally.
Human immunodeficiency virus I infection (pediatrics >= 40 kg, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily, 400 mg twice daily, or 300 mg (3 x 100 mg) chewable tablets twice daily orally.
Human immunodeficiency virus I infection (pediatrics >= 25 kg) 400 mg film-coated tablet twice daily orally; weight-based chewable tablet dosing twice daily if unable to swallow tablet.
Human immunodeficiency virus I infection (pediatrics 3 kg to < 25 kg, >= 4 weeks of age) Weight-based dosing using chewable tablet or oral suspension twice daily orally (approximately 6 mg/kg/dose).
Human immunodeficiency virus I infection (neonates birth to 4 weeks, >= 2 kg) Weight-based oral suspension: once daily dosing (~1.5 mg/kg/dose) from birth to 1 week; twice daily dosing (~3 mg/kg/dose) from 1 to 4 weeks of age.
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (systemic, more than a single dose)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
—
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, dizziness, nausea, rash
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight gain, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, allergic reaction including angioedema, lactic acidosis, pancreatitis, rhabdomyolysis, osteomalacia, acute renal failure, Fanconi syndrome
Most common (>=2%) Headache, insomnia, nausea, dizziness, fatigue.
Serious Myopathy, rhabdomyolysis, hepatitis, hepatic failure, depression including suicidal ideation and behaviors, nephrolithiasis, renal failure, hypersensitivity.
Postmarketing Thrombocytopenia, diarrhea, hepatic failure, rhabdomyolysis, cerebellar ataxia, anxiety, paranoia.
Pharmacology
COMPLERA is a fixed-dose combination antiretroviral containing emtricitabine (nucleoside reverse transcriptase inhibitor), rilpivirine (non-nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor); each component inhibits HIV-1 reverse transcriptase through distinct mechanisms to suppress viral replication.
Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1-encoded enzyme required for viral replication, preventing integration of unintegrated linear HIV-1 DNA into the host cell genome; it is eliminated primarily via UGT1A1-mediated glucuronidation and does not inhibit or induce cytochrome P450 enzymes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Complera
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Isentress
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Complera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Isentress
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Complera
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Isentress
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CompleraView full Complera profile
IsentressView full Isentress profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.